Andra AP fonden Cuts Stock Position in Eli Lilly and Company $LLY

Andra AP fonden lowered its position in Eli Lilly and Company (NYSE:LLY) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 113,513 shares of the company’s stock after selling 13,720 shares during the period. Eli Lilly and Company makes up about 1.5% of Andra AP fonden’s portfolio, making the stock its 11th largest position. Andra AP fonden’s holdings in Eli Lilly and Company were worth $136,151,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $12,976,634,000. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. Jupiter Topco LLC purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $4,667,180,000. Fifth Third Bancorp lifted its holdings in Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in Eli Lilly and Company by 353.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after purchasing an additional 1,208,510 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $5.09 during trading on Tuesday, hitting $1,169.98. The company had a trading volume of 1,111,489 shares, compared to its average volume of 3,013,810. The firm has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.28, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The stock has a fifty day simple moving average of $1,176.50 and a two-hundred day simple moving average of $1,078.33. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is owned by insiders.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly CEO David Ricks said approximately 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July, with Lilly capturing about 70% of those new patients. Foundayo also represents roughly one-third of new oral GLP-1 prescriptions, with its share growing weekly. CNBC Medicare coverage article
• Positive Sentiment: Lilly broke ground on a planned $6.5 billion Houston manufacturing facility that will produce active ingredients for medicines including Foundayo. The project is expected to create more than 600 jobs and strengthen domestic supply capacity. Lilly Houston manufacturing announcement
• Positive Sentiment: Investor Ken Langone said Lilly is becoming one of the largest positions in his portfolio and suggested the stock could eventually reach $2,000. Separately, a major global bank reportedly sees approximately 37% upside after the recent pullback. Ken Langone Lilly outlook
• Neutral Sentiment: Lilly and Dragoneer have indicated interest in Oura’s planned IPO. The investment could provide exposure to consumer health data, but it is not expected to materially affect Lilly’s near-term earnings. Oura IPO article
• Negative Sentiment: Competition remains the principal risk. Viking Therapeutics shares surged after positive obesity-drug data, while Roche also reported encouraging results. The developments raise concerns that Lilly’s current obesity-drug dominance could face stronger competition, pressuring the stock alongside Novo Nordisk. Viking and Roche obesity-drug data

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a report on Friday, August 7th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, Sanford C. Bernstein lifted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,305.25.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.